{'fraction_non_alphanumeric': 0.024509803921568627, 'fraction_numerical': 0.014161220043572984, 'mean_word_length': 5.185185185185185, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
EFFECTIVENESS OF FIXED COMBINATION OF FORMULATIONS FOR COUGHING

There are many respiratory diseases, which despite the difference in aetiology, pathogenesis, the peculiarities in progression may have some common features, resulting in the localization of the pathological process in the respiratory systems. These common signs include changes in bronchial secretion that ultimately leads to mucostasis and burdens the course of any respiratory disease. There are very few combined formulations capable of impacting several mechanisms of mucostasis at once. One of them is Ascoril possessing a double effect of bronchodilator and expectorant. The aim of this study was to evaluate the clinical efficacy and safety of Ascoril therapy for patients with acute respiratory diseases. The study included 105 patients aged 25 ± 0.5 to 55 ± 1.6 years with mild or moderate acute respiratory disease, who had acute respiratory diseases with cough due to laryngitis, pharyngitis, tracheitis, bronchitis. Patients of the 1st group (75 patients, the main group) received the treatment with Ascoril, the patients of the 2nd group (30 patients, the comparison group) received Bromhexine. The patients in both groups were comparable by age and sex. The patients treated with Ascoril showed the disappearance of cough symptoms 3 – 4 days earlier than the patients in the comparison group (p < 0.05). The total score assessment of clinical symptoms during the treatment demonstrated the administration of Ascoril promoted the effectiveness of therapy, which was found significantly higher than in the 2nd group (p < 0.05). We can conclude Ascoril reduces the duration of the disease, cut down the need in antibiotics, lowers the manifestations of bronchial hyper reactivity, and promotes faster clinical recovery, the last but not the least, it is safe.